Chongqing Zhifei Biological Products (300122.CH) - Could Zhifei Support Its Valuation?
219 Views26 Apr 2021 09:05
After its COVID-19 vaccine got approved in March, the investment logic is different. This article analyzed the key catalysts of Zhifei (agency business, COVID-19 vaccine) and thoughts on valuation.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- Shenzhen Mindray Bio-Medical Electronics - The Future Performance Is Worth Looking Forward To10 May 2021
- China Healthcare Weekly (May.7)09 May 2021
- Autobio Diagnostics (603658.CH) - The Turning Point Is Quietly Approaching03 May 2021
- CanSino Biologics (6185.HK) - Will the COVID-19 Vaccine Be the Turning Point?03 Mar 2021
- Industry Report - Insights on China Vaccine Industry28 Jan 2021
- Chongqing Zhifei Biological Products- Promising Future After Successful Renewal of Contract with MSD14 Jan 2021
x